Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025

Dallas, Texas–(Newsfile Corp. – December 2, 2024) – Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc.  (NASDAQ: IXHL). During 1Q 2025 the Company reported research and development costs of $2.9M, an increase of $0.3M from 1Q24. We expect R&D costs to continue to climb as the Company focuses on getting its drug candidates across the finish line. IXHL recovered 28.0% of these costs with an R&D tax incentive of $0.8M. We expect that this will normalize around 43.5% for the foreseeable future.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Incannex’s novel drug to treat Obstructive Sleep Apnea has completed dosing for the Phase 2/3 FDA trial.
• IXHL has received IND clearance from the FDA for its PSX-001 drug, designed to treat Generalized Anxiety Disorder.
• When we use a probability adjusted DCF model, it returns an estimated per share valuation range of $5.07 to $5.93.

Click image above to view full announcement.

About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Contacts:

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232235

View more news from Reportable, Inc.

You are receiving this email because you have previously indicated your interest in receiving news for Reportable, Inc.

If you no longer want to receive messages from us, you can click here to unsubscribe.

Anti-Spam Policy | Privacy Policy